Tadalafil for the treatment of pulmonary arterial hypertension

Expert Opinion on Pharmacotherapy
Maria Klara Frey, Irene Lang

Abstract

Pulmonary arterial hypertension (PAH) is a progressive occlusive disease affecting the pulmonary vasculature; it carries a poor prognosis. Because right ventricular failure is the key feature of deterioration in PAH patients, vasodilator treatments relieving right ventricular afterload have gained ground in the treatment of this disorder. Phosphodiesterase-5 inhibitors are effective and well tolerated vasodilators that were originally developed for erectile dysfunction. Tadalafil , the first once-daily drug of this class, was approved by the USFDA in May 2009 for the treatment of patients suffering from PAH. This review outlines the currently available data about tadalafil and its effects in patients with PAH. It also presents evidence from recent clinical trials of tadalafil and discusses potential improvements over existing therapy options and their impact on current treatment strategies. Tadalafil is an efficacious drug with a favorable side-effect profile and convenient mode of administration. More studies are needed to analyze its impact on survival and to substantiate its role in an upfront combination treatment strategy.

References

Jan 1, 1991·Advances in Experimental Medicine and Biology·H S AhnE J Sybertz
Jul 1, 1991·Journal of the American College of Cardiology·D J StewartP Cernacek
Feb 1, 1995·The Journal of Clinical Investigation·J A Beavo
Jun 3, 1999·American Journal of Respiratory and Critical Care Medicine·R M TuderN F Voelkel
Dec 26, 2001·The Journal of Laboratory and Clinical Medicine·H OlschewskiF Grimminger
Jan 31, 2002·American Journal of Respiratory and Critical Care Medicine·Neil DavieJohn Wharton
Sep 23, 2003·Drugs·Monique Curran, Gillian Keating
Nov 12, 2003·The American Journal of Cardiology·Raymond C Rosen, John B Kostis
Dec 4, 2003·Journal of the American College of Cardiology·Robert A KlonerGraham Jackson
Jan 23, 2004·Cardiovascular Research·Nazzareno GaliéAngelo Branzi
Nov 3, 2004·Annals of Internal Medicine·Emiliano Antonio PalmieriDanilo Lembo
Jan 8, 2005·Clinical Pharmacology and Therapeutics·Barbara J RingDiane L Phillips
Feb 3, 2005·The European Respiratory Journal·V V McLaughlinL J Rubin
Mar 2, 2005·Basic Research in Cardiology·Benedetta TantiniNazzareno Galié
Aug 16, 2005·Journal of Clinical Pharmacology·Manish GuptaBernd Meibohm
Nov 18, 2005·The New England Journal of Medicine·Nazzareno GalièUNKNOWN Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group
Feb 4, 2006·American Journal of Respiratory and Critical Care Medicine·Marc HumbertGérald Simonneau
Jul 28, 2006·British Journal of Clinical Pharmacology·S Thomas ForgueMalcolm I Mitchell
Oct 21, 2006·Current Opinion in Cardiology·B K S Sastry
Jan 4, 2008·Expert Opinion on Drug Safety·Thorsten ReffelmannRobert A Kloner
Feb 29, 2008·Journal of Clinical Pharmacology·Rebecca E WrishkoMalcolm I Mitchell
Sep 25, 2008·Respirology : Official Journal of the Asian Pacific Society of Respirology·Daniele BendayanMordechai R Kramer
May 28, 2009·Circulation·Nazzareno GalièUNKNOWN Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group
Jul 9, 2009·Journal of the American College of Cardiology·Gérald SimonneauRogério Souza
Jul 9, 2009·Journal of the American College of Cardiology·David B BadeschAdam Torbicki
Aug 19, 2009·Current Medical Research and Opinion·Joanna Pepke-ZabaMallik Angalakuditi
Dec 17, 2009·Expert Opinion on Pharmacotherapy·Erika B Rosenzweig
Jan 25, 2011·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Robyn J BarstUNKNOWN Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group
Apr 8, 2011·American Journal of Respiratory and Critical Care Medicine·Zhi-Cheng JingUNKNOWN Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group
Jun 22, 2011·Nature Reviews. Cardiology·Ralph T SchermulyFriedrich Grimminger

❮ Previous
Next ❯

Citations

Oct 18, 2014·Cardiovascular Drugs and Therapy·Fadi N SalloumRakesh C Kukreja
Sep 13, 2016·Molecular Pharmaceutics·Anna KrupaFlorence Danède
Nov 7, 2012·Therapeutic Advances in Respiratory Disease·Dioma U Udeoji, Ernst R Schwarz
Apr 14, 2018·Circulation·Marvin A KonstamUNKNOWN American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Ca
Aug 5, 2017·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Daniela Díaz-LucenaAgustina García
Feb 7, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Adam MieczkowskiKrzysztof Woźniak

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

American Journal of Respiratory and Critical Care Medicine
Zhi-Cheng JingEfficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group
© 2022 Meta ULC. All rights reserved